Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the third quarter of fiscal year 2020. Third quarter 2020 results reflect strong sequential growth: Revenue of $794 million, an increase of 26% compared to the second quarter of 2020 and a 12% decrease compared to $907 million in the prior year period GAAP net income attributable to Illumina stockholders for the quarter of $179 million, or $1.21 per diluted share, compared to $234 million, or $1.

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2020

Las Vegas Sands

StoneCo

Yandex

If you own toxic stocks for a long period of time, you are sure to see huge erosion in your wealth. Figuring out such stocks and selling them at the right time is the key to successful investing.

4 Toxic Stocks That You Need to be Wary of & Dump Right Now

Exelixis

These two stocks have very different methods of generating returns.

Better Buy: Illumina vs. Exelixis

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an individual investor's stock selection process, as it may offer great insights of how the brightest minds of the finance industry feel about specific stocks. After all, these people have access to smartest analysts and expensive data/information sources that individual investors can't match. So should one consider investing in Illumina, Inc. (NASDAQ:ILMN)? The smart money sentiment can provide an answer to this question.

Was The Smart Money Right About Illumina, Inc. (ILMN)?

Bonsai Partners recently released its Q3 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 63.3% for the quarter (net of fees), outperforming their benchmark, the S&P 500 Index which returned 8.9% in the same quarter. You should check out Bonsai Partners' top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Why Illumina (ILMN) Stock is a Compelling Investment Case

China Biologic Products Holdings

Galapagos

Heron Therapeutics

Ionis Pharma

REGENXBIO

Ligand Pharmaceuticals

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio

Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.

Illumina (ILMN) to Report Q3 Earnings: What's in the Offing?

How COVID-19 is treated in the future could be altered by recent breakthrough research.

The 1 Stock Most Likely to Win From a Potentially Game-Changing Coronavirus Discovery

Biogen

Novo Nordisk

ResMed

In light of coronavirus cases increasing both domestically and internationally, four health care companies with strong business quality are Biogen Inc. (NASDAQ:BIIB), Novo Nordisk A/S (NYSE:NVO), ResMed Inc. (NYSE:RMD) and Illumina Inc. (NASDAQ:ILMN) according to the All-in-One Screener, a Premium feature of GuruFocus.

4 Health Care Companies With Strong Business Quality

Intuitive Surgical

Veeva Systems

When you have an opportunity to buy the best stocks on the cheap, don't outsmart yourself.

Next Coronavirus Market Correction: Where to Invest $5,000

The announcement by Illumina that it was acquiring GRAIL was swiftly met by a $20 billion market cap decline within a week.

Illumina And Grail Together: A Perfect Marriage

The gene sequencing giant needs to show that its acquisition of Grail can translate into meaningful business growth.

Why Ilumina's Stock Fell 13.5% in September

Becton, Dickinson and Co.

Exact Sciences

Guardant Health Inc

Natera

Invitae

QuidelOrtho Corp

COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.

7 Diagnostic and Genomic Stocks Storming Into October

Which stock wins in this genetics version of David versus Goliath?

Better Buy: Invitae vs. Illumina

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2020 following the close of market on Thursday, October 29, 2020. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details

Illumina to Announce Third Quarter 2020 Financial Results on Thursday, October 29, 2020

Week In Review: Illumina Pays $8 Billion To Acquire GRAIL, An Early-Stage Cancer Testing Company

Anika Therapeutics

ANIK vs. ILMN: Which Stock Is the Better Value Option?

ANIK vs. ILMN: Which Stock Should Value Investors Buy Now?

Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock.

Illumina Analysts Question Grail Deal's Commercial Opportunity, Hefty Price Tag

When companies become large enough, they very frequently look to acquisitions for new growth opportunities.

Are Analysts Underestimating What Grail Brings for Illumina’s Future Growth?

Shares of Illumina Inc. ILMN, -8.58% were down 0.2% in premarket trading on Tuesday, the day after the stock dropped 8.6% and it confirmed plans to buy cancer-detection company Grail Inc.

Analysts question Illumina's plans to buy cancer-detection company Grail

A lot of investors hate Illumina's planned acquisition of GRAIL. But is the deal really that bad?

Is Illumina Making an $8 Billion Blunder?

Illumina (ILMN) CEO Francis deSouza on Illumina to Acquire GRAIL Conference Call (Transcript)

In an announcement on Monday, Illumina Inc. (NASDAQ: ILMN) said it will pay £6.25 billion in cash and stock to buy Grail Inc.

Illumina expresses plans of acquiring Grail Inc. for £6.25 billion

Illumina's news of its $8 billion deal to acquire Grail, a healthcare company focused on cancer detection, has ILMN stock down on Monday.

Illumina News: ILMN Stock Slides Lower on $8 Billion Grail Deal

Grail's blood test for early detection of 50 types of cancer is poised for launch next year.

News for Illumina Stock (ILMN)